(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 52.2% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Crispr Therapeutics Ag's revenue in 2024 is $371,206,000.On average, 11 Wall Street analysts forecast CRSP's revenue for 2024 to be $8,461,807,614, with the lowest CRSP revenue forecast at $1,766,070,900, and the highest CRSP revenue forecast at $36,758,357,505. On average, 10 Wall Street analysts forecast CRSP's revenue for 2025 to be $45,534,846,843, with the lowest CRSP revenue forecast at $5,539,040,550, and the highest CRSP revenue forecast at $265,857,891,210.
In 2026, CRSP is forecast to generate $112,685,839,569 in revenue, with the lowest revenue forecast at $31,715,422,326 and the highest revenue forecast at $436,950,023,445.